ResMed’s earnings rise as cash generation supports over $1 billion of shareholder returns
ResMed ($RMD) reported approximately $1.4 billion of revenue for the first quarter of fiscal 2027, up 6%, as demand for sleep devices, masks and accessories increased. Adjusted earnings per share rose 14% to $2.91, while GAAP EPS increased 23% to $2.92. Adjusted gross margin improved by half a percentage point to 62.5%, helped by productivity gains across the sleep and breathing-health business. Operating cash flow reached $422 million and free cash flow was $374 million. Cash generation and pro
0